Purpose: A [F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and compared with [Ga]Ga-DOTA-TATE.
Method: [F]AlF-NOTA-JR11 was synthesized manually and qualified with high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). The cellular uptake, internalization, and saturation binding were performed with HEK293-SSTR2 cells. Biodistribution and micro-PET imaging were carried out with HEK293-SSTR2 tumor-bearing mice. [F]AlF-NOTA-JR11 PET/MR imaging and [Ga]Ga-DOTA-TATE PET/CT were performed with ten patients of NEN at 50~60 min post-injection (p.i.). Normal organ biodistribution and tumor detectability were evaluated.
Result: [F]AlF-NOTA-JR11(24~36 GBq/μmol) was prepared within 30 min and 51.35 ± 3.30% (n > 10)of radiochemical yield. The radiochemical purity was 98.74 ± 1.24% (n > 10). Two stereoisomers were found and confirmed by LC-MS. The cellular uptake of [F]AlF-NOTA-JR11 and [Ga]Ga-DOTA-TATE were 4.50 ± 0.31 and 4.50 ± 0.13 %AD/10 cells at 30 min, and the internalization at 37 °C of [F]AlF-NOTA-JR11 (5.47 ± 0.32% at 60 min) was significantly lower than [Ga]Ga-DOTA-TATE (66.89 ± 1.62% at 60 min). The affinity of [F]AlF-NOTA-JR11 (K = 11.59 ± 1.31 nM) was slightly lower than [Ga]Ga-DOTA-TATE (K = 7.36 ± 1.02 nM); [F]AlF-NOTA-JR11 showed high uptake in tumor (9.02 ± 0.92 %ID/g at 60 min p.i.) which can be blocked by 50 μg of NOTA-JR11 (3.40 ± 1.64 %ID/g at 60 min p.i.); the result was coincident with micro-PET imaging. Imaging study of NEN patients showed that more lesions were found only by [F]AlF-NOTA-JR11 (n = 67 vs. 1 only by [Ga]Ga-DOTA-TATE), and the uptakes of [F]AlF-NOTA-JR11 in majority normal organs were significantly lower than [Ga]Ga-DOTA-TATE. The target to nontarget of maximum of standard uptake value (SUVmax) of [F]AlF-NOTA-JR11 in liver lesions were significantly higher than those of [Ga]Ga-DOTA-TATE.
Conclusion: Qualitied [F]AlF-NOTA-JR11 is prepared conveniently with reasonable yield, and it can bind SSTR2 specifically with high affinity. Excellent imaging capability of [F]AlF-NOTA-JR11 for NENs is superior to [Ga]Ga-DOTA-TATE, especially in digestive system. It has a great potential for imaging of NENs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-021-05249-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and preclinical evaluation of [F]AlF-NOTA-Asp-PEG-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor.
Eur J Nucl Med Mol Imaging
November 2024
GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, PET Center, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Purpose: Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [F]AlF-NOTA-Asp-PEG-JR11, and compare its preclinical performance with the previously reported antagonist, [F]AlF-NOTA-JR11, and the agonist [Ga]Ga-DOTA-TATE.
Methods: [F]AlF-NOTA-Asp-PEG-JR11 was synthesized via a one-step radiolabeling process involving [F]AlF chelation.
F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use.
J Nucl Med
June 2023
Nuclear Medicine, University Hospitals Leuven, and Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium;
Molecular imaging of the somatostatin receptor plays a key role in the clinical management of neuroendocrine tumors. PET imaging with somatostatin analogs (SSAs) labeled with Ga or Cu is currently the gold standard in clinical practice. However, widespread implementation of Ga imaging is often hampered by practical and economic issues related to Ge/Ga generators.
View Article and Find Full Text PDFDirect comparison of [F]AlF-NOTA-JR11 and [F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist.
Nucl Med Biol
April 2023
Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium. Electronic address:
Background: [F]AlF-NOTA-octreotide is an F-labeled somatostatin analogue which is a good clinical alternative for Ga-labeled somatostatin analogues. However, radiolabeled somatostatin receptor (SSTR) antagonists might outperform agonists regarding imaging sensitivity of neuroendocrine tumors (NETs). No direct comparison between the antagonist [F]AlF-NOTA-JR11 and the agonist [F]AlF-NOTA-octreotide as SSTR PET probes is available.
View Article and Find Full Text PDFSynthesis, preclinical evaluation, and a pilot clinical imaging study of [F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [Ga]Ga-DOTA-TATE.
Eur J Nucl Med Mol Imaging
September 2021
Department of Nuclear Medicine, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng Rd., Beijing, 100142, China.
Purpose: A [F]AlF-labeled somatostatin receptor (SSTR) antagonist was developed for imaging of neuroendocrine neoplasms (NENs), evaluated and compared with [Ga]Ga-DOTA-TATE.
Method: [F]AlF-NOTA-JR11 was synthesized manually and qualified with high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS). The cellular uptake, internalization, and saturation binding were performed with HEK293-SSTR2 cells.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!